SCHEMBL784488

SCHEMBL784488

CN(CC1CCN(c2ccncn2)CC1)C(=O)c1ccc2c(c1)[C@H](NC(=O)c1ccccc1Cl)CC2

nearest known ligand 0.40

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
TAS1R3 Q7RTX0 5/20 0.40
TAS1R1 Q7RTX1 5/20 0.40
TAS1R2 Q8TE23 4/20 0.40
ALDH1A1 P00352 1/20 0.40
F10 P00742 2/20 0.39
MEN1 O00255 1/20 0.39
KMT2A Q03164 1/20 0.39
SPTLC2 O15270 2/20 0.35
BDKRB1 P46663 4/20 0.35
PAK1 Q13153 1/20 0.35
HTR1A P08908 1/20 0.35
DRD2 P14416 1/20 0.35
HTR2A P28223 1/20 0.35
KCNH2 Q12809 1/20 0.35
PDE2A O00408 1/20 0.35
WDR5 P61964 1/20 0.35
SPTLC3 Q9NUV7 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL784836 0.90 BDKRB1 (0.45) TAS1R3TAS1R1TAS1R2ALDH1A1MEN1
SCHEMBL785289 0.89 ALDH1A1 (0.41) TAS1R3TAS1R1TAS1R2ALDH1A1F10
SCHEMBL785563 0.85 TAS1R3 (0.40) TAS1R3TAS1R1TAS1R2ALDH1A1F10
SCHEMBL785272 0.82 BDKRB1 (0.47) TAS1R3TAS1R1TAS1R2ALDH1A1BDKRB1
SCHEMBL784826 0.80 MEN1 (0.44) TAS1R3TAS1R1TAS1R2ALDH1A1MEN1
SCHEMBL784049 0.79 WDR5 (0.37) TAS1R3TAS1R1TAS1R2F10KCNH2
SCHEMBL785049 0.79 ALDH1A1 (0.41) TAS1R3TAS1R1TAS1R2ALDH1A1MEN1
SCHEMBL784261 0.78 ALDH1A1 (0.43) TAS1R3TAS1R1TAS1R2ALDH1A1F10
SCHEMBL784081 0.78 ALDH1A1 (0.43) TAS1R3TAS1R1TAS1R2ALDH1A1F10
SCHEMBL777867 0.78 ALDH1A1 (0.43) TAS1R3TAS1R1TAS1R2ALDH1A1F10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8680159-B2 Bradykinin 1 receptor modulating compounds GRUENENTHAL GMBH (DE) 2014-03-25 US claimed
US-20120071461-A1 Substituted Benzamide Compounds GRUENENTHAL GMBH (DE) 2012-03-22 US claimed
US-8680159-B2 Bradykinin 1 receptor modulating compounds GRUENENTHAL GMBH (DE) 2014-03-25 US disclosed
US-8680159-B2 Bradykinin 1 receptor modulating compounds GRUENENTHAL GMBH (DE) 2014-03-25 US disclosed
US-8680159-B2 Bradykinin 1 receptor modulating compounds GRUENENTHAL GMBH (DE) 2014-03-25 US disclosed
US-20120071461-A1 Substituted Benzamide Compounds GRUENENTHAL GMBH (DE) 2012-03-22 US disclosed
US-20120071461-A1 Substituted Benzamide Compounds GRUENENTHAL GMBH (DE) 2012-03-22 US disclosed
US-20120071461-A1 Substituted Benzamide Compounds GRUENENTHAL GMBH (DE) 2012-03-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120071461-A1 Substituted Benzamide Compounds BDKRB1, BDKRB2, HRH2 TAS1R3 202/4885TAS1R1 75/4885TAS1R2 163/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.